DPP4 and metabolic dysfunction-associated steatohepatitis: Thus, DPP4i treatment-induced improvement of NASH and decreased hepatic DPP4 expression in our in vivo model might be driven not only from the effect on the hepatocytes but also from that on the HSCs.